Careers  |  Sign In  |  Register

Cabozantinib Shows Promise in Non-Clear-Cell Kidney Cancer

Research

New data shows that cabozantinib, a drug already approved in the treatment of clear cell renal cell carcinoma (ccRCC), elicited promising results in patients with less common non-clear cell renal cell carcinoma (nccRCC). This new data, published in The Lancet Oncology, suggests the antitumor activity of cabozantinib is not limited to the clear-cell renal cell carcinoma subgroup and that some patients with non-clear-cell histology may achieve clinical benefit.

Learn more by clicking here.